DIKUL - logo
E-viri
Celotno besedilo
Recenzirano
  • KCl Cotransporter-3 Down-re...
    Hsu, Yueh-Mei; Chen, Yih-Fung; Chou, Cheng-Yang; Tang, Ming-Jer; Chen, Ji Hshiung; Wilkins, Robert J; Ellory, JClive; Shen, Meng-Ru

    Cancer research (Chicago, Ill.), 11/2007, Letnik: 67, Številka: 22
    Journal Article

    The potassium chloride cotransporter (KCC) is a major determinant of osmotic homeostasis and plays an emerging role in tumor biology. Here, we investigate if KCC is involved in the regulation of epithelial-mesenchymal transition (EMT), a critical cellular event of malignancy. E-cadherin and {szligbeta}-catenin colocalize in the cell-cell junctions, which becomes more obvious in a time-dependent manner by blockade of KCC activity in cervical cancer SiHa and CaSki cells. Real-time reverse transcription-PCR on the samples collected from the laser microdissection indicates that KCC3 is the most abundant KCC isoform in cervical carcinoma. The characteristics of EMT appear in KCC3-overexpressed, but not in KCC1- or KCC4-overexpressed cervical cancer cells, including the elongated cell shape, increased scattering, down-regulated epithelial markers (E-cadherin and {szligbeta}-catenin), and up-regulated mesenchymal marker (vimentin). Some cellular functions are enhanced by KCC3 overexpression, such as increased invasiveness and proliferation, and weakened cell-cell association. KCC3 overexpression decreases mRNA level of E-cadherin. The promoter activity assays of various regulatory sequences confirm that KCC3 expression is a potent negative regulator for human E-cadherin gene expression. The proteosome inhibitor restores the decreased protein abundance of {szligbeta}-catenin by KCC3 overexpression. In the surgical specimens of cervical carcinoma, the decreased E-cadherin amount was accompanied by the increased KCC3 abundance. Vimentin begins to appear at the invasive front and becomes significantly expressed in the tumor nest. In conclusion, KCC3 down-regulates E-cadherin/{szligbeta}-catenin complex formation by inhibiting transcription of E-cadherin gene and accelerating proteosome-dependent degradation of {szligbeta}-catenin protein. The disruption of E-cadherin/{szligbeta}-catenin complex formation promotes EMT, thereby stimulating tumor progression. Cancer Res 2007; 67(22):11064-73